科伦药业
(002422)
| 流通市值：521.37亿 | | | 总市值：638.70亿 |
| 流通股本：12.99亿 | | | 总股本：15.91亿 |
| 利润表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 营业总收入 | 13,112,749,782 | 8,838,531,817 | 4,259,244,936 | 18,512,918,907 |
| 营业总成本 | 12,001,794,511 | 8,121,411,562 | 3,990,126,052 | 16,435,765,003 |
| 其他经营收益 | | | | |
| 营业利润 | 1,388,912,337 | 897,211,572 | 356,491,477 | 2,521,049,666 |
| 利润总额 | 1,979,131,564 | 1,553,184,992 | 441,048,209 | 2,403,835,588 |
| 净利润 | 1,774,635,230 | 1,426,262,565 | 472,700,274 | 1,877,211,208 |
| 每股收益 | | | | |
| 其他综合收益 | -59,083,295 | -39,307,445 | -57,105,201 | -51,730,405 |
| 综合收益总额 | 1,715,551,935 | 1,386,955,120 | 415,595,073 | 1,825,480,803 |
| 资产负债表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 流动资产: | | | | |
| 流动资产合计 | 23,434,783,706 | 21,764,296,111 | 21,284,915,877 | 20,040,018,949 |
| 非流动资产: | | | | |
| 非流动资产合计 | 19,597,451,091 | 19,722,593,483 | 19,856,894,333 | 19,794,804,376 |
| 资产总计 | 43,032,234,797 | 41,486,889,594 | 41,141,810,210 | 39,834,823,325 |
| 流动负债: | | | | |
| 流动负债合计 | 9,578,239,342 | 10,390,978,659 | 10,066,130,094 | 9,189,628,608 |
| 非流动负债: | | | | |
| 非流动负债合计 | 1,080,172,167 | 1,271,986,371 | 1,328,834,598 | 1,351,301,054 |
| 负债合计 | 10,658,411,509 | 11,662,965,030 | 11,394,964,692 | 10,540,929,662 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 25,992,956,724 | 24,616,962,798 | 24,638,160,530 | 24,224,470,760 |
| 股东权益合计 | 32,373,823,288 | 29,823,924,564 | 29,746,845,518 | 29,293,893,663 |
| 负债和股东权益合计 | 43,032,234,797 | 41,486,889,594 | 41,141,810,210 | 39,834,823,325 |
| 现金流量表 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 16,773,584,338 | 11,506,090,680 | 5,010,027,575 | 22,380,191,670 |
| 经营活动现金流出小计 | 14,037,024,971 | 9,164,918,770 | 4,760,416,258 | 19,738,123,385 |
| 经营活动产生的现金流量净额 | 2,736,559,367 | 2,341,171,910 | 249,611,317 | 2,642,068,285 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 17,392,743,900 | 11,755,835,068 | 7,754,878,982 | 24,445,800,113 |
| 投资活动现金流出小计 | 20,409,454,811 | 14,145,998,109 | 8,549,234,081 | 25,734,061,085 |
| 投资活动产生的现金流量净额 | -3,016,710,911 | -2,390,163,041 | -794,355,099 | -1,288,260,972 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 8,121,467,362 | 4,978,289,767 | 2,604,972,331 | 6,802,544,469 |
| 筹资活动现金流出小计 | 6,765,771,754 | 4,715,301,573 | 1,558,662,893 | 6,118,515,188 |
| 筹资活动产生的现金流量净额 | 1,355,695,608 | 262,988,194 | 1,046,309,438 | 684,029,281 |
| 汇率变动对现金及现金等价物的影响 | -67,949 | -4,887,003 | -806,895 | -45,926,939 |
| 现金及现金等价物净增加额 | 1,075,476,115 | 209,110,060 | 500,758,761 | 1,991,909,655 |
| 期末现金及现金等价物余额 | 7,012,147,844 | 6,145,781,789 | 6,437,430,490 | 5,936,671,729 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | - | 209,110,060 | - | 1,991,909,655 |
最新报告期：2026-10-30| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 中国银河 | 孙怡,程培 | 1.13 | 1.25 | 1.54 | 2026-10-30 |
| 华泰证券 | 代雯,孙茗馨,沈卢庆 | 1.15 | 1.51 | 1.95 | 2026-10-29 |
| 东海证券 | 杜永宏 | 1.29 | 1.47 | 1.76 | 2026-09-08 |
| 中金公司 | 张琎,朱言音 | 1.20 | 1.50 | -- | 2026-09-01 |
| 中国银河 | 孙怡,程培 | 1.27 | 1.43 | 1.77 | 2026-08-31 |